Adma Biologics (ADMA) Total Liabilities (2011 - 2026)
Adma Biologics' (ADMA) quarterly Total Liabilities came in at $146.9 million in Q4 2025, up 5.2% YoY from $139.7 million in Q4 2024, and up 6.85% on a QoQ basis from $137.5 million in Q3 2025.
Adma Biologics (ADMA) Total Liabilities (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Total Liabilities data on file, last reported at $146.9 million in Q4 2025.
- Quarterly Total Liabilities rose 5.2% year-over-year to $146.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $146.9 million (up 5.2% YoY) and the FY2025 annual result came in at $146.9 million, up 5.2% from the prior year.
- Total Liabilities advanced to $146.9 million in Q4 2025, from $137.5 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $200.2 million in Q3 2022 to a low of $121.2 million in Q2 2021.
- A 5-year average of $166.2 million and a median of $170.6 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2021 — Total Liabilities sank 36.71% — and 2022, when it soared 50.58%.
- Tracing ADMA's Total Liabilities over 5 years: stood at $135.1 million in 2021, then jumped by 45.46% to $196.5 million in 2022, then decreased by 1.28% to $194.0 million in 2023, then declined by 28.0% to $139.7 million in 2024, then climbed by 5.2% to $146.9 million in 2025.
- The last three Total Liabilities figures came in at $146.9 million (Q4 2025), $137.5 million (Q3 2025), and $160.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 276.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 276.00 Mn |
| Dec 31, 2025 | 146.92 Mn |
| Sep 30, 2025 | 137.50 Mn |
| Jun 30, 2025 | 160.06 Mn |
| Mar 31, 2025 | 137.15 Mn |
| Dec 31, 2024 | 139.66 Mn |
| Sep 30, 2024 | 158.73 Mn |
| Jun 30, 2024 | 188.13 Mn |
| Mar 31, 2024 | 197.17 Mn |
| Dec 31, 2023 | 193.98 Mn |
| Sep 30, 2023 | 197.56 Mn |
| Jun 30, 2023 | 196.26 Mn |
| Mar 31, 2023 | 195.13 Mn |
| Dec 31, 2022 | 196.49 Mn |
| Sep 30, 2022 | 200.17 Mn |
| Jun 30, 2022 | 182.53 Mn |
| Mar 31, 2022 | 181.10 Mn |
| Dec 31, 2021 | 135.08 Mn |
| Sep 30, 2021 | 135.86 Mn |
| Jun 30, 2021 | 121.22 Mn |